Litigation
Celgene Corp. v. Dr. Reddy's Laboratories, Inc.
settledAuto-generating section 1 of 5: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2016-10-20
- Terminated
- 2020-09-17
Patents at issue (1)
Plaintiffs (1)
Defendants (1)
Summary
Celgene sued Dr. Reddy's Laboratories in D.N.J. over generic lenalidomide, with U.S. 7,855,217 among the asserted patents. The case settled, and a consent judgment was entered on September 17, 2020, with Dr. Reddy's agreeing not to market generic Revlimid until expiration of the asserted patents. The docket number was not directly confirmed in the narrative.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).